ArticleFrontiers in medicine2025
Effect of remimazolam besylate versus midazolam on time to extubation in critically ill, mechanically ventilated patients: a randomized controlled trial.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sedation with remimazolam besylate versus midazolam in acute respiratory distress syndrome patients supported by venovenous extracorporeal membrane oxygenation: a study protocol for a multicenter prospective randomized trial.Journal of thoracic disease · 2026Article
- Safety and efficacy of remimazolam in critical illness.Journal of intensive care · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies have indicated that the administration of short-acting sedatives prior to weaning from mechanical ventilation is linked to a more rapid recovery and extubation process, in addition to lowering intensive care unit (ICU) treatment expenses. The present study aimed to evaluate the efficacy and safety of the sequential administration of remimazolam besylate compared with midazolam before weaning from mechanical ventilation. Methods: This multicenter, randomized controlled trial was conducted across medical and surgical ICUs within a tertiary, academic medical center. The study population consisted of critically ill, mechanically ventilated adult patients. Candidates anticipated to be ready for ventilator weaning within 12 h underwent a Spontaneous Breathing Trial (SBT) safety screen. Only those who successfully passed this assessment were considered for inclusion in the final phase of the study and subsequent randomization. The patients were randomized into two groups: group M, in which the sedative regimen was transitioned to midazolam, and group R, which involved a switch to remimazolam. Sedative dosages were titrated to achieve a target Richmond Agitation-Sedation Scale (RASS) score between -3 and 0. The primary endpoint of this study was the time to extubation. Results: A total of 435 patients underwent screening, of whom 306 patients being randomized, and 272 patients ultimately included in the analysis, comprising 132 patients in group M and 140 patients in group R. The patients in group R maintained lighter levels of sedation compared to those in group M. The patients in group R showed significantly earlier recovery ( Conclusion: In critically ill, mechanically ventilated patients, the use of remimazolam besylate was associated with a shorter time to recovery and extubation prior to ventilator weaning, along with a lower incidence of agitation. Clinical trial registration: Identifier ChiCTR 2200065048, https://www.chictr.org.cn.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.